Low-dose or "microdose" GLP-1 use means taking less than the labeled dose, or spacing doses further apart. It is off-label, no randomized trials have tested it, and current evidence is limited to rationale, small observational data and clinician experience.
"Microdosing" a GLP-1 medication usually means using smaller amounts than the labeled doses, or stretching the time between doses, often to improve tolerability, lower cost or keep a steady routine. It is an off-label practice. According to a 2025 comment in Diabetes Care, no randomized controlled trials support it and it is not included in clinical guidelines, and the published evidence consists mostly of expert commentary, clinical rationale and a small amount of observational data. That does not mean it never has a place, but it does mean the honest answer to "does it work?" is "we do not know well yet."
There is no official definition. A 2026 commentary in Expert Opinion on Pharmacotherapy describes microdosing as using a fraction of the manufacturer's recommended starting dose, or extending the dosing interval. The authors note that it gained traction during recent shortages through patient communities, telemedicine weight programs and clinician anecdotes, and that techniques include "click counting" with multidose pens or spacing doses further apart.
A 2025 letter in Diabetes Care explained the practical side: some multidose pens deliver a dose through a series of unnumbered clicks, which makes fractional doses possible but not precise.
The rationale described in the literature is reasonable on its face:
These are hypotheses and clinical reasoning, not proven outcomes. The 2026 commentary describes early reports of reduced nausea, better adherence and modest weight change, while stating that high-quality clinical evidence remains limited.
Dose matters in the full-dose trials. In SURMOUNT-1, published in the New England Journal of Medicine in 2022, adults with obesity were assigned to one of three tirzepatide maintenance doses or placebo for 72 weeks. The average weight change was -15.0 percent on the lowest maintenance dose, -19.5 percent on the middle dose and -20.9 percent on the highest, versus -3.1 percent with placebo. The lowest dose in that trial was still a full labeled maintenance dose, well above what people usually mean by microdosing, so these results cannot be stretched to cover smaller amounts. What the trial does illustrate is that average effects were smaller at lower doses.
One observational study looked at people who stayed at a starting dose. A 2026 analysis in Biology Methods and Protocols used de-identified health records from a network of 29 million patients. It identified people who were repeatedly prescribed only the lowest approved starting dose of semaglutide (814 people) or tirzepatide (1,016 people) for at least six months. Mean 12-month weight change was -5.5 percent in the tirzepatide group and -2.2 percent in the semaglutide group. The tirzepatide group had higher rates of some side effects, including constipation and acute kidney injury, while the semaglutide group had higher rates of others. The authors were explicit that this prescribing pattern "may overlap with, but does not establish, intentional microdosing," and that the findings are observational associations that call for prospective studies.
Lower amounts are sometimes assumed to be automatically safer, but that has not been established. The main concerns raised in the literature are practical:
The low-dose GLP-1 program available through NewDay Wellness uses compounded medication, which is not FDA-approved, and any dose is set and monitored by the prescriber.
No. Microdosing is an off-label use. The FDA explains that clinicians may generally prescribe an approved drug in an unapproved way when they judge it medically appropriate, but the agency has not determined that it is safe and effective for that use. Compounded versions are not FDA-approved at any dose.
There is not enough evidence to say. One observational study of people who stayed on the lowest starting dose found modest average weight changes over 12 months, but it was not a trial and did not study intentional microdosing. Full-dose trials show smaller average effects at lower doses.
That is the hope behind the practice, and gastrointestinal effects do tend to relate to dose, but it has not been tested in randomized trials. Inaccurate measurement can also cause unexpected side effects. Report any persistent or severe symptoms to your prescriber.
Do not change your dose or schedule on your own. Any change should come from your prescriber, who can weigh your goals, side effects and other medications.
If you are curious about a lower-dose approach, the useful conversation is about your goals, how you have tolerated medication, and what the limited evidence can and cannot tell you. A licensed provider can explain whether a standard or modified approach makes sense, and how it would be monitored. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
Compounded semaglutide and tirzepatide are not FDA-approved. The FDA declared both national shortages resolved by early 2025, so compounding is now limited mainly to patient-specific prescriptions under section 503A, and in 2026 the FDA proposed keeping both off the 503B bulks list.
Read article
Obesity behaves like a chronic condition, and the trial data on stopping GLP-1 medications show why. What long-term management looks like, what a licensed provider monitors, and how to think about maintenance.
Read articleGLP-1 medications copy a hormone your gut already makes. Here is what that hormone does, how the medications change appetite and digestion, and which products are FDA-approved versus compounded.
Read article